Podcasts about Retinal

Drs. Akshay Thomas and Sarwar Zahid join for a journal club podcast discussion of three recent high-impact articles:Visual Fields in Diabetic Retinopathy (https://www.ophthalmologyretina.org/article/S2468-6530(25)00208-8/abstract)Gender Differences in Case Volume (https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2833393)Private Equity Practices and Retinal Detachment Volume (https://www.healthaffairs.org/doi/abs/10.1377/hlthaff.2024.01204?journalCode=hlthaff)Relevant Financial Disclosures: NoneYou can claim CME credits for prior episodes via the AAO website. Visit https://www.aao.org/browse-multimedia?filter=Audi

One of the challenges of delivering gene therapies to the eye is that once a subretinal injection is made, the therapy's distribution is confined to the margins of the pocket of fluid that is created, known as a bleb. Atsena, which is developing gene therapies for X-linked retinoschisis and Leber congenital amaurosis 1, uses its AAV.SPR technology that allows the gene therapy to spread laterally after injection. We spoke to Patrick Ritschel, CEO of Atsena Therapeutics, about the challenges of gene therapies for inherited retinal diseases, how the company's unique vector technology addresses this, and how it allows for safer and more effective delivery of gene therapies to the retina.

Unlock the fascinating connection between your eyes and your brain in this episode! Did you know that your retina can reveal early signs of brain disease—even years before symptoms appear? Discover how the eye, formed from brain tissue, acts as a window into your neurological and circulatory health. We'll dive into new research showing that simple eye exams may one day predict aging and age-related diseases like macular degeneration, diabetic retinopathy, hypertension, multiple sclerosis, Parkinson's, and even Alzheimer's.You'll learn about the role of the optic nerve, the latest breakthroughs in retinal imaging, and how changes in the eye might signal Alzheimer's up to 8–9 years before a diagnosis. Plus, we'll discuss why prevention—through diet, exercise, and targeted supplements—is more important than ever for protecting both your mind and vision.Ready to nourish your brain and eyes? Here's our recommended list of essential nutrients:Taurine, lutein, zeaxanthin, mesozeaxanthin, B vitamins, bilberry, ginkgo biloba, omega-3 fatty acids, alpha-lipoic acid, N-acetylcysteine, glutathione, bacopa, lycopene, selenium, zinc, and the mushroom lion's mane.Stay informed and take charge of your health—tune in and visit us at naturaleyecare.com for the latest tips on protecting your eyes and brain!

Today, we are joined by the esteemed Dr. Jay Chhablani, a distinguished professor of ophthalmology and vitreoretinal surgeon at the Department of Ophthalmology, University of Pittsburgh. As the Director of Clinical Research at the UPMC Vision Institute, Dr. Chhablani stands at the forefront of cutting-edge advancements in eye care. Embark on a fascinating exploration as Dr. Chhablani, a retina specialist and surgeon, shares his wealth of knowledge on retinal diseases, ranging from bothersome floaters to age-related macular degeneration. Delve into the intricacies of ophthalmic surgeries, including the delicate art of retinal detachment repair. Press play to discover: The origins and prevention of eye floaters, along with effective treatment approaches. Conditions warranting surgical intervention for floaters. Navigating through complications associated with common ophthalmic surgeries and procedures. Distinguishing between the two primary forms of macular degeneration. The mechanics of novel drug therapies in slowing the progression of retinal diseases. Eager to learn more? Tune in and explore more at Jay Chhablani, MD | Department of Ophthalmology | University of Pittsburgh. Episode also available on Apple Podcasts: apple.co/30PvU9C

Dr. Nadia Khalil and Dr. Jean Bouchart discuss the diagnostic approach to intracerebral hemorrhage, the causes of cerebral small vessel disease, and the interpretation of biomolecular tests.  Show reference: https://www.neurology.org/doi/10.1212/WNL.0000000000209796 

Drs. Ramsudha Narala, Kat Talcott, and Sarwar Zahid join to preview the June 2025 edition of Retinal Physician, focusing on GLP-1RAs and diabetic retinopathy, DRCR.net trial updates, CRAO protocol implementation, and early career advice for attendings. Relevant Financial Disclosures: None

Dr. Nadia Khalil talks with Dr. Jean Bouchart about the diagnostic approach to intracerebral hemorrhage, the causes of cerebral small vessel disease, and the interpretation of biomolecular tests.  Read the related article in Neurology® Resident & Fellow Section.  Disclosures can be found at Neurology.org. 

In this episode of the BroadEye Podcast, hosts Shawn Maloney and Dr. Bruno Fernandes welcome Prof. Michel Michaelides, one of the most active clinical researchers in ophthalmology today. Prof. Michaelides leads a large inherited retinal disease clinic—seeing 30–40 children and adults each week—and splits her time between patient care, advanced imaging research, and steering more than ten ongoing clinical trials.   Why This Matters Inherited retinal diseases affect hundreds of thousands worldwide, and for most there is still no approved treatment. Over the past two years, we've seen multiple Phase 1/2 gene-therapy trials move into registrational studies, alongside novel antioxidant approaches and AI-driven biomarkers. Today's conversation cuts through the jargon to give you a clear picture of where the field stands—and where it's headed.   Key Takeaways Beyond RPE65: While Luxturna paved the way, newer AAV-based therapies for X-linked RP (RPGR) and other targets are now in Phase 2 and Phase 3 trials, with early data showing promising safety and efficacy. Imaging & Function: Prof. Michaelides is pioneering next-generation retinal imaging devices and novel functional assays to capture meaningful changes in vision—critical for shortening trial timelines. Antioxidant Strategies: High-dose N-acetylcysteine trials are under way, offering a non-viral approach to slow photoreceptor degeneration across multiple genetic subtypes. AI in Stratification: Machine-learning algorithms on retinal scans can help predict progression rate and identify the best candidates for specific therapies, improving both trial design and patient outcomes. Balancing Dose & Safety: Finding the sweet spot between transgene expression and immune activation remains a core challenge—Prof. Michaelides shares lessons learned from dose-escalation cohorts. Phase 3 & Beyond: With over a hundred patients enrolled in pivotal studies, we're closing in on potential approvals—but long-term follow-up and real-world evidence will determine ultimate impact.   About the Guest Prof. Michelle Michaelides is a clinician-scientist specializing in inherited retinal diseases. She leads dedicated adult and pediatric IRD clinics, oversees the development of advanced imaging and functional biomarkers, and serves as principal investigator on over ten clinical trials spanning gene therapies, antioxidant agents, and AI-guided stratification tools. Prof. Michaelides regularly lectures at international conferences and collaborates with industry and academic partners to accelerate the translation of research into real-world treatments.

In this latest episode of the BroadEye podcast, hosts Shawn Maloney and Dr. Bruno Fernandes sit down with Dr. Arshad M. Khanani, MD, MA, FASRS, a pioneer in vitreoretinal gene-therapy trials and Managing Partner at Sierra Eye Associates. Dr. Khanani shares front-line insights into how genetic medicines are reshaping treatment for inherited and degenerative retinal diseases, highlighting both the promise and the practical challenges of bringing one-time therapies to patients.   Why Gene Therapy Matters Today Recent years have seen the first US approvals of in-vivo retinal gene therapies, beginning with voretigene neparvovec (Luxturna) for RPE65-mediated inherited retinal dystrophy in December 2017. These one-off treatments offer durable vision improvements where none existed before, but they also raise questions of long-term safety, vector delivery, and equitable access.   Dr. Khanani's Journey With over a decade leading surgical trials in sustained-delivery and viral-vector therapies, Dr. Khanani has overseen early human work on next-generation agents—including subretinal injections of AAV vectors and novel capsid designs. He describes lessons learned from Phase 1 safety studies through global registrational trials, emphasizing iterative “vector evolution” to boost efficacy and minimize inflammation.   Key Takeaways Vector Optimization: Directed-evolution platforms are accelerating discovery of capsids that target photoreceptors more precisely, reducing off-target toxicity. Durability vs. Dose: Striking the right balance between transgene expression and immune activation remains central—higher doses don't always equal better outcomes. Regulatory Pathways: While Luxturna set a precedent, streamlined FDA and EMA guidance on trial endpoints and real-world evidence will shape the next wave of approvals. Cost & Access: Innovative payment models (e.g., outcomes-based installment plans) are emerging to address the multi-hundred-thousand-dollar price tags of these therapies.   About the Guest Dr. Arshad M. Khanani, MD, MA, FASRS, is a vitreoretinal surgeon, researcher, and Managing Partner at Sierra Eye Associates in Reno, Nevada. He holds dual degrees in medicine and medical humanities from the University of Nevada, Reno, and is a fellow of the American Society of Retina Specialists. Dr. Khanani has authored over 100 peer-reviewed articles on retinal disease and served as principal investigator on more than 30 clinical trials of gene and cell therapies for inherited and age-related retinal disorders. He also lectures internationally on surgical innovation, vector design, and the economics of advanced ocular treatments.

2521 Advancing Treatments for Inherited Retinal Diseases (May 21, 2025) Show Notes Research is key to fighting blinding eye diseases. Hosts Nancy and Peter Torpey talk with Jason Menzo, CEO of the Foundation Fighting Blindness, about advancing treatments for inherited retinal diseases, funding research initiatives, and launching new mental health resources to support individuals with … Continue reading 2521 Advancing Treatments for Inherited Retinal Diseases (May 21, 2025) →

Interview with researcher Levi Todd, PhD.

Drs. Akshay Thomas and Sarwar Zahid join to preview the May 2025 edition of Retinal Physician, focusing on future developments in stem cells, microbots, artificial intelligence, and more.Relevant Financial Disclosures: None

In this episode of Medsider Radio, we sat down with Vicky Demas, CEO of identifeye HEALTH (formerly Tesseract Health), who's leading the company's efforts to democratize access to retinal imaging. Using advanced algorithms and automated systems, identifeye's technology captures and analyzes retinal images to detect early signs of disease.Before joining identifeye HEALTH, Vicky led new product development at GRAIL, supporting the creation of the company's multi-cancer early detection test (Galleri). She was also a founding member of Google Life Sciences (later Verily) within Google [x], where she led teams focused on diagnostics, medical devices, and translational laboratory science. An engineer and scientist, Vicky holds over 20 patents and has authored numerous scientific publications across multiple disciplines.In this interview, Vicky challenges founders to consider: Are you building a diagnostic solution that can scale globally or a product limited to specialized healthcare settings? She also discusses why understanding real-world implementation challenges early can prevent costly missteps later.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You'll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and 3 packages that will help you make use of our database of 750+ life science investors more efficiently for your fundraise and help you discover your next medical device or health technology investor!In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume VII. If you're interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Vicky Demas.

BUFFALO, NY — April 14, 2025 — A new #research paper was #published in Aging (Aging-US) Volume 17, Issue 3, on March 4, 2025, titled “Deciphering age-related transcriptomic changes in the mouse retinal pigment epithelium.” The study, led by first authors Sushil K. Dubey and Rashmi Dubey with corresponding author Mark E. Kleinman from East Tennessee State University, reveals that aging causes inflammation, oxidative stress, and gene disruption in the retinal pigment epithelium (RPE), a vital layer of cells in the eye. These changes may explain why older adults are more vulnerable to age-related eye diseases. The researchers also developed a human cell model to study retinal aging and test future therapies. The RPE plays a key role in maintaining retinal health. It recycles light-sensitive molecules, supports the visual cycle, and protects the retina from damage. When this layer becomes damaged, vision problems such as age-related macular degeneration can develop. In this study, researchers compared gene activity in RPE cells from young and aged mice. They found that aging increased the activity of genes involved in immune system responses, inflammation, and oxidative stress, three known triggers of tissue damage. At the same time, genes related to vision and light detection became less active, weakening the RPE's ability to support healthy vision. To reinforce these findings, the research team also aged human RPE cells in the lab. Over time, these cells showed the same patterns: inflammation increased, while genes tied to visual function decreased. This human cell model offers a practical way to explore how RPE degeneration happens over time and how it might be slowed down or reversed. The research also identified “hub genes,” which are central players of the gene networks involved in RPE aging. These are connected to immune signaling, oxidative damage, and changes in the eye's structural support. Many of these genes are already known to be involved in age-related retinal degeneration, so they may become important targets for future treatments aimed at protecting vision in older adults. “GO annotation of downregulated genes included processes related to visual perception, sensory perception of light stimulus, detection of light stimulus, detection of visible light, detection of external stimulus, detection of abiotic stimulus, phototransduction, cellular response to interferon-beta, response to interferon-beta, and response to light stimulus.” By mapping how the RPE changes with age at the molecular level, this study provides a clearer understanding of why aging leads to eye disease. It also introduces a reliable laboratory model that researchers can use to test new therapies. Altogether, the work is a key step toward developing treatments to slow or prevent vision loss tied to retinal aging. Read the full paper: DOI: https://doi.org/10.18632/aging.206219 Corresponding author: Mark E. Kleinman- kleinman@etsu.edu Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords: aging, transcriptome, retinal pigment epithelium, oxidative stress, inflammation, chronological aging To learn more about the journal, please visit our website at https://www.Aging-US.com​​ and connect with us on social media at: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc Media Contact 18009220957 MEDIA@IMPACTJOURNALS.COM

Drs. Kovacs and Starr join for the latest gimmick the retina world is going wild for: how do you manage this retinal detachment scenario?Relevant Financial Disclosures: NoneYou can claim CME credits for prior episodes via the AAO website. Visit https://www.aao.org/browse-multimedia?filter=Audi

Hearing the buzz around skin cycling? We have been too. This week, we're joined by Dr. Whitney Bowe as she breaks down the concept of skin cycling. Listen in as she discusses her treatment philosophy, what it means for skin routines to be "smarter not more," and offers valuable advice for curious dermatologists looking to challenge conventional wisdom. Each Thursday, join Dr. Raja and Dr. Hadar, board-certified dermatologists, as they share the latest evidence-based research in integrative dermatology. For access to CE/CME courses, become a member at LearnSkin.com. Whitney Bowe, MD is a renowned, board-certified dermatologist and scientist based in New York. She is one of the most in-demand dermatologists in the country, in addition to being a founding member of the Dermstore Medical Advisory Board and a distinguished thought leader in the space. For the past seven years, her practice has been fully booked and capped, but now with her skin-care line, Dr. Whitney Bowe Beauty, you can bring the doctor home with you. Dr. Bowe championed a focus on the skin-gut-mind connection. Her “three-dimensional” approach to skincare—treating skin from both the outside and inside—challenged long-held beliefs within the field of dermatology. She is also responsible for bringing the viral skin-care concept of Skin Cycling to the world, which has amassed more than 3 billion TikTok views. With a deep knowledge of the skin, skin care products and dermatology, Dr. Bowe is constantly quoted in top media outlets like Vogue, The New York Times and Good Morning America. Enjoy 15% off your Dr. Whitney Bowe Beauty order at drwhitneybowebeauty.com with code LEARNSKIN15, valid April 3-17, 2025. Don't miss out!      

Drs. Akshay Thomas and Priya Vakharia join to preview the April 2025 edition of Retinal Physician, focusing on current and future therapies for neovascular AMD.Relevant Financial Disclosures: Dr. Sridhar has consulted for Genentech, Regeneron, and Eyepoint. Dr. Vakharia has consulted for Regeneron, Ocular Therapeutix, and Eyepoint.You can claim CME credits for prior episodes via the AAO website. Visit https://www.aao.org/browse-multimedia?filter=Audi

We love to hear from our listeners. Send us a message.In this episode of Cell & Gene: The Podcast, Host Erin Harris dives into the world of retinal gene therapy with Kenji Fujita, M.D., Chief Medical Officer of Atsena Therapeutics. Atsena develops treatments for inherited retinal diseases, including X-linked retinoschisis (XLRS), a rare genetic condition that currently has no FDA-approved therapy. They talk through the impact of XLRS on patients, the challenges of gene delivery to the retina, and how Atsena's AAV vector technology is designed to overcome these hurdles. They also discuss the significance of the Fast Track designation recently granted to Atsena's XLRS program, the role of patient advocacy in rare disease research, and the key milestones to watch for in the months ahead.Subscribe to the podcast!Apple | Spotify | YouTube

BUFFALO, NY — March 25, 2025 — A new #research paper was #published in Aging (Aging-US) on January 31, 2025, in Volume 17, Issue 2, titled “Cysteinyl leukotriene receptor 1 modulates retinal immune cells, vascularity and proteolytic activity in aged mice.” The study, led by first author and corresponding author Andreas Koller from the University Hospital of the Paracelsus Medical University, found that blocking an inflammatory receptor called CysLTR1 in the retinas of aging mice improved retinal health. These findings suggest a new approach to slowing age-related vision loss and protecting eye health in older adults. Age-related vision problems are a growing concern worldwide, and inflammation plays a key role in damaging the retina over time. The retina is the part of the eye that captures light and sends visual signals to the brain, making it vital for clear eyesight. In this study, scientists focused on the CysLTR1 receptor, which is known to promote inflammation and is found in high amounts in the retina. They explored whether blocking this receptor could reduce the harmful effects of aging in the eye. To achieve this, researchers treated aged mice with montelukast (MTK), a drug commonly used for asthma, which specifically blocks CysLTR1. The oral treatment lasted eight weeks and results were compared with both untreated aged mice and healthy young mice. After treatment, the older mice showed major improvements in retinal health. One key finding was a reduction in immune cells called microglia, which tend to increase with age and contribute to chronic inflammation in the retina. With CysLTR1 blocked, the number of these immune cells dropped significantly, suggesting reduced retinal inflammation. Lower inflammation is linked to a lower risk of age-related eye diseases like macular degeneration. “The reduction in immune cells caused by Cysltr1 suppression may dampen neuroinflammation, a known promoter of tissue aging.” Another important result was the restoration of blood vessel function. The tiny blood vessels in the retina had narrowed in aging mice, reducing blood flow and oxygen supply to the eye. MTK treatment increased the diameter of these vessels, improving circulation and possibly helping the retina work more efficiently. The study also indicated that blocking CysLTR1 helped boost the retina's natural ability to clear out waste proteins. As we age, this cleaning process slows down, allowing harmful material to build up in the eye. After treatment, the aged mice had stronger proteasome activity—the system responsible for breaking down cellular waste—and fewer signs of waste accumulation. Importantly, the treatment did not harm retinal nerve cells, which are essential for vision. This evidence indicates that the therapy was not only effective but also safe. While more research is needed to confirm these results in humans, this study highlights the potential of repurposing MTK to protect against age-related vision decline. Because it is already an approved drug, testing it for age-related eye diseases like macular degeneration or diabetic retinopathy could move forward more quickly. Blocking inflammation and supporting the eye's natural cleaning systems may be a promising new way to preserve healthy vision in aging populations. DOI - https://doi.org/10.18632/aging.206193 Corresponding author - Andreas Koller - a.koller@salk.at Video short - https://www.youtube.com/watch?v=ngnrPJzHlpI Please visit our website at https://www.Aging-US.com​​ and connect with us: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

Which of the two following findings would be anticipated in the normal fundoscopic exam of a healthy 40-year-old woman who is normotensive, generally in good health and without ocular complaint?  A. Arteriovenous nickingB. Optic cup to disc ratio < .0.5C. Retinal arteries are brighter and narrower than veins  D. Slight bulging of the optic diskVisit fhea.com to learn more!

Drs. Rebecca Soares, Akshay Thomas, and Sarwar Zahid join the podcast for a journal club discussion covering three recent articles in major ophthalmology journals.Macula-Off Retinal Detachment Prognostic Factors (https://journals.lww.com/retinajournal/abstract/9900/preoperative_and_early_postoperative_factors.944.aspx)Progression to PDR from NPDR after Cataract Surgery (https://www.aaojournal.org/article/S0161-6420(25)00125-3/abstract)Sexual Harassment in Ophthalmology (https://jamanetwork.com/journals/jamaophthalmology/article-abstract/2830480)Relevant Financial Disclosures: NoneYou can claim CME credits for prior episodes via the AAO website. Visit https://www.aao.org/browse-multimedia?filter=Audi

*This month in partnership with Choroideremia Research Foundation**Our Carrier Connections program features a different X-linked condition each month with the goal to increase awareness of X-linked conditions and how they impact the lives of women and girls.This month, we are featuring choroideremia (CHM). CHM is an X-linked disorder caused by mutations in the gene, CHM, which produces a protein that plays a critical role in the cell's ability to transport proteins and organelles within and outside of the cell. When this gene is dysfunctional, the cell can no longer support this protein escort ability, resulting in premature cell death primarily in the eyes. Typically, this condition is characterized by progressive vision loss. These symptoms may begin at any age, but tend to onset between childhood and adulthood. Females carriers of CHM have been proven to experience a spectrum of symptoms, ranging from mild to severe retinal degeneration. Today, we are featuring Dr. Sena Gocuk. Dr. Gocuk is an optometrist and postdoctoral research fellow specialising in inherited retinal diseases (IRD), with a particular focus on female carriers of X-linked IRDs. Her research explores the unique challenges female carriers face, from variability in disease expression to their underrepresentation in clinical trials. Dr. Gocuk has led innovative studies investigating retinal changes in female carriers, providing insights into emerging treatments such as gene therapy. She is an advocate for the inclusion of female carriers in research and treatment interventions, regularly sharing her findings to promote better care and access for this often-overlooked population.RESOURCES:Choroideremia Research FoundationRetinal Characteristics of Female Choroideremia Carriers: Multimodal Imaging, Microperimetry, and GeneticsLongitudinal assessment of female carriers of choroideremia using multimodal retinal imagingFemale carriers of X-linked inherited retinal diseases - Genetics, diagnosis, and potential therapiesCarrier Connections is sponsored by Kyowa Kirin and Amgen. For more information about our organization, check out ⁠⁠⁠⁠⁠⁠rememberthegirls.org⁠⁠⁠⁠⁠⁠.

Ogul Uner, MD, invites Scott Oliver, MD, to the podcast to review a case of a 60-year-old man who presented with new flashes, floaters, and blurriness in his inferior field of vision in his right eye. The patient is a high myope with a relative afferent pupillary defect and pigmented cells in the anterior vitreous, with OCT imaging showing a macula-off retinal detachment. Dr. Oliver shares his approach to this case, reviews risk factors for retinal detachments, and shares insights into treatment.

Drs. Katherine Talcott and Akshay Thomas join to discuss the March 2025 edition of Retinal Physician focusing on dry age-related macular degeneration, including photobiomodulation, complement inhibition, and deep learning for imaging.Relevant Financial Disclosures: Dr. Sridhar has consulted for Apellis.You can claim CME credits for prior episodes via the AAO website. Visit https://www.aao.org/browse-multimedia?filter=Audi

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/DJG865. CME credit will be available until March 3, 2026.Retinal Disease in Emergency Medicine: Timely Recognition and Referral for Specialty CareThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American College of Emergency Physicians and PVI, PeerView Institute for Medical Education. The American College of Emergency Physicians is accredited by the ACCME to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis program is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/DJG865. CME credit will be available until March 3, 2026.Retinal Disease in Emergency Medicine: Timely Recognition and Referral for Specialty CareThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American College of Emergency Physicians and PVI, PeerView Institute for Medical Education. The American College of Emergency Physicians is accredited by the ACCME to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis program is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/DJG865. CME credit will be available until March 3, 2026.Retinal Disease in Emergency Medicine: Timely Recognition and Referral for Specialty CareThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American College of Emergency Physicians and PVI, PeerView Institute for Medical Education. The American College of Emergency Physicians is accredited by the ACCME to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis program is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/DJG865. CME credit will be available until March 3, 2026.Retinal Disease in Emergency Medicine: Timely Recognition and Referral for Specialty CareThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American College of Emergency Physicians and PVI, PeerView Institute for Medical Education. The American College of Emergency Physicians is accredited by the ACCME to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis program is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

انسداد شریان مرکزی شبکیه

This podcast is brought to you by Outcomes Rocket, your exclusive healthcare marketing agency. Learn how to accelerate your growth by going to outcomesrocket.com Early detection of Alzheimer's disease is crucial, and accessible diagnostic tools like retinal imaging are becoming increasingly vital.  In this episode, Eliav Shaked, co-founder of RetiSpec, discusses their innovative approach to early and accurate Alzheimer's detection using retinal imaging and artificial intelligence. RetiSpec focuses on identifying the core pathology of Alzheimer's, specifically amyloid burden, through a simple eye examination that can be incorporated into annual checkups. The company is also working on other neurodegenerative diseases beyond Alzheimer's. Eliav emphasizes the significance of recent breakthroughs in Alzheimer's medication, highlighting the potential of disease-modifying drugs now available, along with the growing innovation and therapeutic development in the space. He also predicts that more drugs will be developed for earlier stages of the disease and that technology will revolutionize healthcare.  Tune in and learn how this innovative technology is paving the way for better Alzheimer's care! Resources:  Connect and follow Eliav Shaked on LinkedIn. Follow RetiSpec on LinkedIn and visit their website.  Fast Track Your Business Growth: Outcomes Rocket is a full-service marketing agency focused on helping healthcare organizations like yours maximize your impact and accelerate growth. Learn more at outcomesrocket.com

Marc R. Bloomenstein, OD, FAAO, invites Steven Ferrucci, OD, FAAO, to discuss the role of optometrists in diagnosing and referring patients with geographic atrophy, diabetic retinopathy, and other retinal conditions. They will also discuss the integration of artificial intelligence and at-home monitoring technology to help manage these patients.

Ja, som avsnittets namn avslöjar så kommer veckans avsnitt att fokusera på Retinol! Emma och Frida tar det hela ett steg längre och fördjupar sig i Retinol, Bakuchiol och Retinal. Vad är det ena, vad är det andra? Vem ska ha vad och när ska en ha det? Vad är det som är så speciellt med just dessa produkter och på vilket sätt påverkar de huden? Det blir tips på olika formulas och styrkor (såklart förklarar Frida och Emma vad poängen är med just “styrkor”), samt vid vilka tillfällen det kan vara en bra idé att ändra på produktens styrka. Det blir också tips på sprillans nya produkter som Frida och Emma känner har en it-faktor. Spänn fäst er och gör er redo för ett redigt Retinolspecial!Klipps av Gabriella Lahti. Hosted on Acast. See acast.com/privacy for more information.

How do couples navigate the tumultuous journey of unexpected medical crises? For Wayne and Ivanna, it began with Wayne's emergency retina surgery, quickly followed by Ivanna's shocking breast cancer diagnosis at age 33. They found solace and strength in each other, embracing health advocacy and community support. Through their ordeal, they transformed their challenges into a mission to inspire and educate others. Key Questions Answered 1. What health advocacy steps does Ivanna recommend for women? 2. How did Ivanna and Wayne handle the emotional and mental health aspects of dealing with illness? 3. How did Ivanna's initial breast cancer diagnosis occur, and what was her reaction? 4. What was Wayne's role and response in supporting Ivanna during her health challenges? 5. How did Ivanna and Wayne's health challenges affect their family plans and vacations? 6. What critical health decision did Ivanna make regarding her cancer treatment, and what was the outcome? 7. What was the significance of self-advocacy as highlighted by both Ivanna and the host Dorothy Gibbons? Timestamped Overview 00:00 Met beautiful woman while bartending one Sunday. 03:43 Date night mishap: fancy wine, no glassware. 08:17 Breast lump concerns repeatedly dismissed by doctors. 10:14 Got biopsy results earlier than expected. 13:10 Struggled with pregnancy and potential health issues. 16:29 Post-pregnancy breast changes important for diagnosis. 21:41 Seeking definitive guidance on radiation treatment necessity. 25:20 Concerned about children's fast-paced upbringing. 27:53 Vacation plan canceled due to emergency surgery. 29:49 Retinal detachment diagnosed; emergency surgery needed. 33:43 Not ready for breast cancer survivor group.See omnystudio.com/listener for privacy information.

Dr. Carlos Quezada-Ruiz is a Vitreoretinal Surgeon and Assistant Professor of Ophthalmology at the Instituto de Oftalmologia Fundación Conde de Valenciana's Retina Department in Mexico City. He also serves as the Senior Vice President of Clinical Research and Development and Therapeutic Area Head (Ophthalmology) at 4DMT, leading early- and late-stage clinical development teams focused on treating neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and geographic atrophy (GA). In addition to his active clinical practice, Dr. Quezada-Ruiz has spent the past decade as a Drug Developer, beginning at Genentech–Roche. There, he worked on the Ophthalmology management team as Group Medical Director of Clinical Science (Product Development). During his tenure, he led the design, execution, and analysis of U.S. and global registrational trials for multiple retinal diseases, including the nAMD global clinical development program for VABYSMO, resulting in U.S. and worldwide approvals. He also led the global clinical science team for SUSVIMO, supporting its initial global filing, FDA approval, and launch in nAMD; successfully navigated the U.S. voluntary recall and commercial relaunch; and oversaw the phase 3 DR/DME registrational program through execution, readout, and filing with the FDA in early 2024. Previously, Dr. Quezada-Ruiz led Medical Affairs efforts for the U.S. launch of Lucentis Prefilled Syringe (PFS) and the myopic choroidal neovascularization indication for LUCENTIS. Furthermore, Dr. Quezada-Ruiz contributed to diversity and inclusion strategies in the Ophthalmology Franchise—such as the AAO MOM program—and advanced personalized healthcare in retina at Genentech by helping design and develop predictive models that use machine learning and large language models to support both drug development and clinical practice. Dr. Quezada-Ruiz is a Fellow of the American Society of Retina Specialists, with over 13 years of clinical practice and research in vitreoretinal diseases and surgery. He earned his M.D. from Universidad Autónoma de Coahuila in his hometown of Torreón, Mexico. He completed fellowships in Vitreoretinal Surgery, Ocular Pathology Research, and Vitreoretinal Surgery Research at Universidad Nacional Autónoma de México, McGill University, and the California Retina Research Foundation, respectively. In 2023, he completed an Executive Education program (CIBE) at Columbia Business School. His accolades include the 2023 Roche Award of Excellence in recognition of outstanding contributions to Roche Pharmaceuticals (“Vabysmo and Beyond”), Genentech's 2023 Medical Excellence Award, the 2019 American Society of Retina Specialists Senior Honor Award, the 2016 ASRS Honor Award, the 2013 Gillingham Pan-American Fellowship by the Pan-American Association of Ophthalmology and The Retina Research Foundation of Houston, Texas, and the 2013 Leonard Ellen Ocular Pathology Award by the Royal Victoria Hospital Foundation. On a personal note, Dr. Quezada-Ruiz is married to Cecy—formerly a marketing specialist at The Coca-Cola Company—and they have three children and a white Labrador, Mia, who is blind from retinal dystrophy. He is also a retired martial artist, philosopher, and health enthusiast. About 4DMT 4DMT is a clinical-stage genetic medicines company focused on harnessing the full potential of genetic therapies for large market diseases, particularly in ophthalmology (wet AMD and DME) and pulmonology (cystic fibrosis lung disease). Therapeutic Vector Evolution (TVE): 4DMT's proprietary vector platform leverages the Nobel Prize–winning technology of directed evolution to create customized viral vectors. This approach propels a diverse product pipeline aimed at revolutionizing medicine with potentially curative therapies for millions of patients.  

Imagine a future where a simple photo of your eye can detect chronic diseases like diabetes and heart conditions!  In this episode, Vicky Demas, CEO of identifeye HEALTH, shares how her company is using AI and automation to revolutionize diagnostic imaging. Discover how identifeye HEALTH is tackling workflow inefficiencies, improving access to care, and enabling early detection of chronic diseases like diabetes and cardiovascular conditions.  Tune in to explore the future of personalized medicine and patient-centered healthcare!

Drs. Safa Rahmani and Sarwar Zahid join the podcast to preview the January 2025 edition of Retinal Physician, found online at http://www.retinalphysician.com.Relevant Financial Disclosures: Dr. Sridhar has consulted for Genentech and Regeneron.You can claim CME credits for prior episodes via the AAO website. Visit https://www.aao.org/browse-multimedia?filter=Audi

Show Notes: Predictions • Both wars will run out of steam and end, officially or unofficially. • There will be insurrections in Iran. • Neither the Dodgers, nor the Celtics, nor the Chiefs will repeat. • Electric car requirements and limits on ICEs will be lifted or eased. • Retinal scanning and fingerprints will allow many to circumvent TSA. • Attempts to copyright and/or trademark AI composites of text and images will eventually reach the Supreme Court. • A betting scandal will rock professional sports. • As China's economy weakens it will engage in more limited military actions against Taiwan. • Universities will face a perfect storm: AI will enable cheating and plagiarism, students and parents will revolt against huge tuitions, government forgiveness of tuition debt will end, there will be attempts to fire tenured professors who teach radical and biased political views, and large cuts will have to be made. The biggest threat: Remote learning which will dramatically lower tuition and enable a greater choice of institutions. • As the population ages and the Millennials rise in business, the country becomes more conservative and centrist in its views and voting. • There will be more intensive recruiting and higher pay for police officers. • Two more members of Congress will be indicted for corruption. • The Taylor Swift phenomenon will begin to wane. • The largest contribution to population growth in the US will be from legal immigrants. • Hacking will accelerate, and will include all kinds of organizations. The government will grant immunity to convicted hackers to help them combat other hackers. • The smart Democrats will realize that it wasn't that “their message didn't get out,” but rather that most people didn't like the message. • Not a prediction, but a wish: Term limits for all of Congress so we can finally end the incestuous power grabbing that has undermined progress for the people. • Happy New Year.

Dr. NJ Manoharan joins the podcast to discuss working in a county hospital system as a retinal surgeon.Relevant Financial Disclosures: NoneYou can claim CME credits for prior episodes via the AAO website. Visit https://www.aao.org/browse-multimedia?filter=Audi

Retinal neurons derived from human stem cells are a promising source of replacement cells for regenerating damaged or diseased retinas. As scientists progress toward translation of cell therapies for restoring vision, they encounter challenges, including how to deliver the cells, ensure that they integrate appropriately with host tissue, and enable proper function after transplantation. In this episode, Iris Kulbatski from The Scientist spoke with Deepak Lamba, a distinguished scientist in the department of immunology and regenerative medicine at Genentech and an associate adjunct professor at the University of California, San Francisco, to learn more about how advances in cell culture models and associated technologies help researchers progress towards retinal cell therapy. The Scientist Speaks is a podcast produced by The Scientist's Creative Services Team. Our podcast is by scientists and for scientists. Once a month, we bring you the stories behind news-worthy molecular biology research. This month's episode is sponsored by Bio-Rad.

Drs. Avni Finn and Sarwar Zahid join the podcast to preview the November 2024 edition of Retinal Physician, found online at http://www.retinalphysician.com.Relevant Financial Disclosures: NoneYou can claim CME credits for prior episodes via the AAO website. Visit https://www.aao.org/browse-multimedia?filter=Audi

On today's episode I am speaking with Nicolas Travis, the founder of Allies of Skin. Backed by his degree in biomedical and pharmaceutical science, but also personal life events – Nicolas gets vulnerable about what drove him to create a brand that would improve people's confidence and skincare with purpose and real results. We dive into which products you need to be using, retinol vs retinal, what peptides actually do, skincare myths, and so much more. Tune in for an incredibly inspiring founder story and key tips and tricks for your skincare routine! Enjoy!To connect with Nicolas on Instagram, click HERE.To shop Allies of Skin, click HERE.To connect with Siff on Instagram, click HERE.To connect with Siff on Tiktok, click HERE.To learn more about Arrae, click HERE. To check out Siff's LTK, click HERE.To check out Siff's Amazon StoreFront, click HERE. This episode may contain paid endorsements and advertisements for products and services. Individuals on the show may have a direct, or indirect financial interest in products, or services referred to in this episode.Produced by Dear MediaSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Drs. Safa Rahmani and Katherine Talcott join the podcast to preview the October 2024 edition of Retinal Physician, found online at http://www.retinalphysician.com. The theme for this issue was clinical trials and anti-VEGF therapy.Relevant Financial Disclosures: Dr. Sridhar has consulted for Eyepoint, Genentech, and Regeneron.You can claim CME credits for prior episodes via the AAO website. Visit https://www.aao.org/browse-multimedia?filter=Audi